Vol. 1, Issue 1 (2012)
Biomarkers: Its Novel Application.
Anand Kumar* and Dr. R. C. Khanna
Advances in biotechnology and improved understanding of cancer and disease biology have shifted the treatment paradigm to targeted therapy. We have enhanced our ability to guide application of new and existing treatments with development, assay verification, biological validation and application of biomarkers. However, to be successful, we need a thorough understanding of the relationship between putative biomarkers and treatment effects. We must consider new clinical trial designs that may consist of randomized cohorts, prospectively planned endpoints, and/or post-hoc analyses. These strategies will succeed if reliable, adequately powered, biologically validated biomarkers are identified and appropriately applied for prospective patient selection via clinical trials. Continued inclusion of preplanned biological correlates will allow ongoing optimization of targeted therapy. These events will guide future directions of proteomics, affecting how we integrate proteomic information into the selection of therapy for advanced and recurrent cancers, and other diseases.
How to cite this article:
Anand Kumar* and Dr. R. C. Khanna. Biomarkers: Its Novel Application.. 2012; 1(1): 22-28.